Flora Growth Corp (NASDAQ:FLGC) intends to explore a preventative application against COVID-19

Recently, Flora Growth Corp. (NASDAQ:FLGC) (“Flora” or the “Company”), a leading all-outdoor cultivator and manufacturer of global cannabis products and brands, announced the addition of Vessel founder and CEO, James Choe, to its executive team. “We are excited not only to have added an incredible company like Vessel to our brand portfolio but to be welcoming such a skilled entrepreneur as James Choe to our executive team,” said Luis Merchan, CEO of Flora Growth. “James brings an unparalleled passion to the organization. He has always been a people-first leader, and his ability to craft a company culture and strategy built-in service of the team has already started to create tangible results. We look forward to him growing his contributions.” Founded by Choe in 2018, Vessel is an industry leader in premium cannabis consumption technology and accessories (1)

So what’s the buzz around FLGC?

As per a recent press issued by the company (2):

– Flora’s research division, Flora Pharma, filed USPTO provisional patent application on a cannabinoid-based formula

– Flora seeks approval to take their patent-pending, cannabinoid-based product through clinical trials under a EUA from INVIMA (Colombian FDA)

– Breakthrough research intends to explore a preventative application against the SARS-CoV-2 (COVID-19) virus for the patent-pending cannabinoid formulation

– If approved, Flora’s formulation would be the first product containing cannabinoids approved by the Colombian government for use against the SARS-CoV-2 (COVID-19) virus. Could Flora Growth Corp. and its investors may be in for a heck of a bullish ride in 2022? As always, conduct your own due diligence.

Click HERE to Read more about FLGC
Coronavirus vaccine stocks to watch for include Pfizer (NYSE:PFE), BioNTech (NASDAQ:BNTX), Moderna (NASDAQ:MRNA), Johnson & Johnson’s (NYSE:JNJ), AstraZeneca (NASDAQ:AZN), Novavax (NASDAQ:NVAX), Ocugen (NASDAQ:OCGN) and Vaxart (NASDAQ:VXRT).


Source 1 – https://www.benzinga.com/pressreleases/22/02/b25472509/flora-growth-names-vessel-founder-james-choe-chief-strategy-officer

Source 2 – https://www.benzinga.com/pressreleases/22/02/b25361355/flora-growth-announces-patent-pending-cannabinoid-based-product-seeks-invima-colombian-fda-emergen

For consideration of being featured on WallstreetPR, contact: Editor@Wallstreetpr.com

Please make sure to read and completely understand our disclaimer at https://www.wallstreetpr.com/disclaimer. FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any content posted on our website is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. WallStreetPR strongly recommends you consult a licensed or registered professional before making any investment decision. Neither WallStreetPR.com nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. WallStreetPR often gets compensated for advertisement services that are disclosed on our disclaimer located at WallStreetPR.com/Disclaimer.

Published by Alan Masterson

Alan has over 25 years of trading experience in the U.S. equity markets. He began his career in finance working on a program trading desk specializing in over-the-counter stocks. His career progressed from that point to his current position as senior trader on an institutional trading desk. In the evenings, Alan teaches economics at a local community college. He has contributed articles to various publications over the last six years, including feature articles for an economics magazine and various financial blogs. You may contact Alan via his email (alanmasterson@wallstreetpr.com) or his Google+ page (https://plus.google.com/103338576216002376250).